PCOS Pathophysiology and Endocrine Disruption
Polycystic ovary syndrome (PCOS) affects 8–13% of reproductive-age women and involves androgen excess, irregular ovulation, and polycystic ovarian morphology. The underlying endocrine disruption involves elevated LH/FSH ratios, excess androgen production from theca cells, and insulin resistance that drives further androgen excess. PFAS, as endocrine disruptors, interfere with multiple components of this hormonal network.
PFAS activate androgen receptor signaling at environmentally relevant concentrations in ovarian cell models, potentially contributing to the androgen excess central to PCOS. PFAS also disrupt insulin signaling in ovarian theca cells, consistent with the insulin resistance that characterizes PCOS and is a target of first-line PCOS treatment.
Human Evidence Linking PFAS to PCOS
Cross-sectional studies comparing serum PFAS levels in women with confirmed PCOS diagnoses versus controls without PCOS have found higher PFAS levels in PCOS patients in several studies. A Chinese study of reproductive-age women found that PFOA and PFOS levels were significantly higher in women with ultrasound-diagnosed polycystic ovarian morphology, and PFAS levels correlated with androgen levels and LH/FSH ratio.
Prospective cohort studies with pre-diagnosis PFAS measurements are limited, making it difficult to determine whether elevated PFAS in PCOS patients preceded or followed disease onset. However, the consistency of cross-sectional associations and the mechanistic plausibility support PFAS as a potential environmental contributor to PCOS risk.
Implications for Reproductive Medicine
Gynecologists and reproductive endocrinologists evaluating women for PCOS should consider environmental PFAS exposure as a potential contributing factor, particularly in communities with water contamination. In women with atypical PCOS presentations or inadequate responses to standard treatments, environmental exposure assessment may reveal modifiable contributors.
Women with PCOS undergoing fertility treatment — where hormonal stimulation protocols depend on predictable endocrine responses — may benefit particularly from PFAS exposure reduction. Eliminating water-borne PFAS during ovarian stimulation and early pregnancy support removes a source of ongoing endocrine interference during critical treatment windows.